Clinical Radiology and Imaging Journal (CRIJ)
ISSN: 2640-2343
Research Article
Preliminary Study of 89Zr Labeled Bevacizumab to Detect
Angiogenesis in a Pre-Clinical Model of Sarcoma
Authors:
George D Wilson
,
Katie L Buelow
,
John Torma
,
Ram Sharma
,
Russ A Kuker
,
Dian Wang
,
Brian Marples
and
Aaron H Wolfson
DOI:
10.23880/crij-16000181
Abstract
The goal of the investigation was to demonstrate uptake of 89Zr labeled bevacizumab as non-invasive probe for angiogenesis in a xenograft model of sarcoma.
Methods: HT-1080 human fibrosarcoma cell were established as xenografts in both athymic nude mice and BALB/c nude mice. Bevacizumab (Bev) was conjugated to 89Zr oxalate using the bifunctional chelate, p-isothiocyanatobenzyl-desferrioxamine (Df-Bz-NCS). Mice were injected with 1.8 - 3.7 MBq of 89Zr-Bev and imaged over 11 days.
Results: Uptake of 89Zr-Bev was clearly demonstrated in HT-1080 xenografts with peak tumor SUVMAX at 4 days post injection when normal tissue uptake had reduced. Declining levels of radioactivity persisted in the tumor for the 11-day observation period. Significant uptake was seen in bone tissue.
Conclusions: These preliminary results demonstrate that 89Zr-Bev is a potential new tracer for noninvasive imaging of VEGF in the microenvironment of sarcomas.
Keywords: Angiogenesis; Bevacizumab; Sarcoma; Micropet; Zirconium-89
View PDF
